¿Es frecuente el uso de IVUS para guiar la ATC?

Optimization by IVUS after FFR Guided PCI: Are There Clinical Benefits for Patients?

Percutaneous coronary interventions have improved during the last decade with 15% rate of target vessel failure (TVF) at 5 years according to the latest reports. We are already familiar with the benefits of functional assessment of lesions with FFR and its clinical outcomes.  Additionally, low post PCI FFR values (FFR ≤ 0.83-≤0.91) have been associated<a href="https://solaci.org/en/2022/08/24/optimization-by-ivus-after-ffr-guided-pci-are-there-clinical-benefits-for-patients/" title="Read more" >...</a>

La endarterectomía precoz parece superior a la angioplastia carotidea en pacientes sintomáticos

Clinical Results of IVUS-Guided Drug-Eluting Stent Implantation in Femoropopliteal Disease

Endovascular treatment of femoropopliteal lesions has become the first-line treatment due to the development of devices that decrease the restenosis rate. Recently, the IMPERIAL study showed greater patency at 1 year and greater freedom from clinically guided revascularization at 2 years in favor of the ELUVIA stent (paclitaxel-eluting fluoropolymer, FP-DES) compared with the ZILVER PTX<a href="https://solaci.org/en/2022/08/23/clinical-results-of-ivus-guided-drug-eluting-stent-implantation-in-femoropopliteal-disease/" title="Read more" >...</a>

Inflamación crónica, enfermedad coronaria y cáncer: distintas caras de una misma moneda

MitraClip in Patients with COPD: a Valid Option

Chronic obstructive pulmonary disease (COPD) and cardiovascular disease are associated to hospitalization and mortality.  When associated to severe mitral regurgitation, not only do these two conditions have poor evolution, but they also limit the possibility of surgical valve replacement, given its high risk. Edge-to-edge repair with MitraClip has been shown beneficial in a group of<a href="https://solaci.org/en/2022/08/17/mitraclip-in-patients-with-copd-a-valid-option/" title="Read more" >...</a>

Stroke criptogénico y el fin de la controversia sobre el cierre del foramen oval

Combination of Percutaneous Suture Devices after TAVR to Reduce Vascular Complications

Current use of transcatheter aortic valve replacement (TAVR) has increased in intermediate-risk patients and has even been used in low-risk patients. Vascular access-related complications and bleeding are still frequent after transfemoral TAVR, being associated with poor short- and long-term outcomes. Using percutaneous closure devices has allowed operators to close the access site without surgery. The<a href="https://solaci.org/en/2022/08/16/combination-of-percutaneous-suture-devices-after-tavr-to-reduce-vascular-complications/" title="Read more" >...</a>

Non-Cardiac Surgery After TAVR Is Safe

There are increasingly more patients who have undergone transcatheter aortic valve replacement (TAVR) and require a non-cardiac intervention, or patients with other diseases who need surgery and are diagnosed with aortic stenosis.  In addition, on many occasions, surgery must be performed as soon as possible (as in cases of cancer) or is an emergency procedure.<a href="https://solaci.org/en/2022/08/11/non-cardiac-surgery-after-tavr-is-safe/" title="Read more" >...</a>

The Best of Main Arena - SOLACI-SOCIME 2022

The Best of the SOLACI-SOCIME 2022 Main Arena: Structural—Selected Topics of TAVR

On the last session from day 1 of SOLACI-SOCIME 2022 on structural pathology, Dr. Raj Makkar, an international expert on the subject, talked about transcatheter aortic valve replacement (TAVR) in pure aortic regurgitation (AR), which presents several implantation challenges, such as insufficient anchoring, embolization, residual regurgitation, ring rupture, etc.  As opposed to patients with aortic<a href="https://solaci.org/en/2022/08/09/the-best-of-the-solaci-socime-2022-main-arena-structural-selected-topics-of-tavr/" title="Read more" >...</a>

The Best of the Main Arena at SOLACI-SOCIME 2022: TAVR Complex Anatomy

In the transcatheter aortic valve replacement (TAVR) session we had a presentation by Dr. John P. Vavalle (USA), head of the Structural Heart Disease Program at the University of North Carolina at Chapel Hill.  In his presentation, he showed how far the limits of percutaneous aortic valve implantation can be stretched by briefly showing successful<a href="https://solaci.org/en/2022/08/09/the-best-of-the-main-arena-at-solaci-socime-2022-tavr-complex-anatomy/" title="Read more" >...</a>

The 12th Edition of ProEducar-SOLACI Fellows Course Was Held

Amidst the 27th annual meeting of the Latin American Society of Interventional Cardiology and the annual meeting of the Mexican Society of Interventional Cardiology, the 12th edition of our course for fellow interventionists ProEducar was held.  The course – directed by Dr. Leandro Lasave (ARG) and codirected by Drs. Gabriel Maluenda (CHL), Guering Eid Lidt<a href="https://solaci.org/en/2022/08/08/the-12th-edition-of-proeducar-solaci-fellows-course-was-held/" title="Read more" >...</a>

Discover SOLACI Congress Satellite Symposia

DISCOVER SOLACI CONGRESS’ SATELLITE SYMPOSIA Together with the attractive agenda of life and edited cases, joint sessions, and international guests, we will be holding 3 key activities characteristic of SOLACI Congresses: ProEducar Fellows course, 12th edition Pediatrics and Congenital Cardiomyopathies Symposium Nurses and Technicians Symposium Discover the complete program for each of these activities. We<a href="https://solaci.org/en/2022/07/30/discover-solaci-congress-satellite-symposia/" title="Read more" >...</a>

ATC sobre arterias nativas o puentes venosos, ¿cuál tiene mejor pronóstico?

Tricuspid Regurgitation: Edge-to-Edge Treatment with PASCAL

About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart failure (HF)—often requiring hospitalization—and with mortality. Surgery in this valve is not simple and has high morbidity and mortality rates due to its comorbidities. Currently, a percutaneous strategy for its resolution is under development, but we still do<a href="https://solaci.org/en/2022/07/21/tricuspid-regurgitation-edge-to-edge-treatment-with-pascal/" title="Read more" >...</a>